Free Trial

Visionary Wealth Advisors Has $9.63 Million Stock Position in Ultralife Co. (NASDAQ:ULBI)

Ultralife logo with Computer and Technology background

Visionary Wealth Advisors lifted its stake in shares of Ultralife Co. (NASDAQ:ULBI - Free Report) by 17.1% in the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 1,292,836 shares of the technology company's stock after buying an additional 188,384 shares during the period. Visionary Wealth Advisors owned about 7.77% of Ultralife worth $9,632,000 as of its most recent SEC filing.

Several other institutional investors also recently modified their holdings of the stock. IFP Advisors Inc bought a new stake in shares of Ultralife in the fourth quarter worth $85,000. Bank of America Corp DE grew its stake in shares of Ultralife by 30.7% in the fourth quarter. Bank of America Corp DE now owns 12,067 shares of the technology company's stock worth $90,000 after purchasing an additional 2,836 shares during the last quarter. Barclays PLC grew its stake in shares of Ultralife by 13.7% in the fourth quarter. Barclays PLC now owns 15,233 shares of the technology company's stock worth $113,000 after purchasing an additional 1,838 shares during the last quarter. LSV Asset Management bought a new stake in shares of Ultralife in the fourth quarter worth $145,000. Finally, Nuveen Asset Management LLC grew its stake in shares of Ultralife by 59.1% in the fourth quarter. Nuveen Asset Management LLC now owns 21,647 shares of the technology company's stock worth $161,000 after purchasing an additional 8,037 shares during the last quarter. 30.68% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling at Ultralife

In other news, Director Bradford T. Whitmore purchased 8,957 shares of the business's stock in a transaction on Tuesday, May 13th. The shares were acquired at an average price of $5.40 per share, with a total value of $48,367.80. Following the completion of the transaction, the director now owns 1,029,884 shares of the company's stock, valued at $5,561,373.60. The trade was a 0.88% increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Thomas Louis Saeli purchased 5,000 shares of the business's stock in a transaction on Wednesday, May 14th. The shares were purchased at an average cost of $5.44 per share, for a total transaction of $27,200.00. Following the transaction, the director now directly owns 85,000 shares of the company's stock, valued at approximately $462,400. The trade was a 6.25% increase in their position. The disclosure for this purchase can be found here. Over the last quarter, insiders have bought 35,160 shares of company stock valued at $191,543. 39.90% of the stock is currently owned by insiders.

Analyst Upgrades and Downgrades

Separately, StockNews.com raised shares of Ultralife from a "hold" rating to a "buy" rating in a research note on Monday, May 12th.

Read Our Latest Stock Report on Ultralife

Ultralife Trading Down 3.1%

ULBI traded down $0.17 during trading on Wednesday, reaching $5.39. 79,453 shares of the stock traded hands, compared to its average volume of 69,599. The company has a quick ratio of 1.62, a current ratio of 3.30 and a debt-to-equity ratio of 0.04. The stock has a market capitalization of $89.65 million, a PE ratio of 9.80 and a beta of 0.77. The stock's 50-day moving average is $4.92 and its 200 day moving average is $6.54. Ultralife Co. has a 12 month low of $4.07 and a 12 month high of $12.40.

Ultralife (NASDAQ:ULBI - Get Free Report) last issued its quarterly earnings results on Friday, May 9th. The technology company reported $0.13 EPS for the quarter, missing analysts' consensus estimates of $0.15 by ($0.02). The firm had revenue of $50.75 million for the quarter, compared to the consensus estimate of $54.50 million. Ultralife had a net margin of 5.44% and a return on equity of 7.92%. During the same period last year, the company posted $0.21 EPS.

Ultralife Profile

(Free Report)

Ultralife Corporation, together with its subsidiaries, designs, manufactures, installs, and maintains power, and communication and electronics systems worldwide. The company operates in two segments, Battery & Energy Products and Communications Systems. The Battery & Energy Products segment offers lithium 9-volt, cylindrical, thin lithium manganese dioxide, rechargeable, and other non-rechargeable batteries; lithium-ion cells, multi-kilowatt module lithium-ion battery systems, and uninterruptable power supplies; and rugged military and commercial battery charging systems and accessories, including smart chargers, multi-bay charging systems, and various cables.

Read More

Institutional Ownership by Quarter for Ultralife (NASDAQ:ULBI)

Should You Invest $1,000 in Ultralife Right Now?

Before you consider Ultralife, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Ultralife wasn't on the list.

While Ultralife currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

(Almost)  Everything You Need To Know About The EV Market Cover

Looking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

This $13 Trillion Energy Breakthrough Will Make Millionaires
Magnificent 7 Stocks Shift Toward Stability and Selective Growth
4 Biotech Stocks on the Verge of Massive Breakthroughs

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines